Top

Neurological Sciences

Published in:

06-11-2023 | Migraine | Original Article

Evaluation of the risk of hypertension in patients treated with anti-CGRP monoclonal antibodies in a real-life study

Authors: Simona Guerzoni, Flavia Lo Castro, Daria Brovia, Carlo Baraldi, Luca Pani

Published in: Neurological Sciences | Issue 4/2024

Abstract

Objective

To explore the rate of hypertension incoming in patients treated with monoclonal antibodies against the calcitonin gene-related peptide.

Background

The monoclonal antibodies blocking the calcitonin gene-related peptide are unquestionable effective in the prevention of migraine. Despite this, the development of hypertension has been detected in some patients.

Methods

This was a retrospective study conducted at the University Hospital of Modena. Patients were visited quarterly up to 1 year.

Results

Globally, no significant increase in the blood pressure was detected. The 5.7% of the patients developed a significant increase in their blood pressure. In particular, patients with a pre-existing hypertension were more likely to have a significant increase in the blood pressure.

Conclusion

The risk of developing hypertension during a treatment with anti-calcitonin gene-related peptide monoclonal antibodies seems low. Anyway, patients with a pre-existing hypertension should be cautiously monitored because they are more likely to develop hypertension.

Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1–211. https://doi.org/10.1177/0333102417738202CrossRef

Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, Katsarava Z, MaassenVanDenBrink A, Martelletti P, Mitsikostas DD, Ornello R, Reuter U, Sanchez-Del-Rio M, Sinclair AJ, Terwindt G, Uluduz D, Versijpt J, Lampl C (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain 23:67. https://doi.org/10.1186/s10194-022-01431-xCrossRefPubMedPubMedCentral

Do TP, Guo S, Ashina M (2019) Therapeutic novelties in migraine: new drugs, new hope? J Headache Pain 20:37. https://doi.org/10.1186/s10194-019-0974-3CrossRefPubMedPubMedCentral

Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB (2015) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 35:478–488. https://doi.org/10.1177/0333102414547138CrossRefPubMed

MaassenVanDenBrink A, Meijer J, Villalón CM, Ferrari MD (2016) Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci 37:779–788. https://doi.org/10.1016/j.tips.2016.06.002CrossRefPubMed

de Hoon JN, Pickkers P, Smits P, Struijker-Boudier HA, Van Bortel LM (2003) Calcitonin gene-related peptide: exploring its vasodilating mechanism of action in humans. Clin Pharmacol Ther 73:312–321. https://doi.org/10.1016/s0009-9236(03)00007-9CrossRefPubMed

Argunhan F, Brain SD (2022) The vascular-dependent and -independent actions of calcitonin gene-related peptide in cardiovascular disease. Front Physiol 13:833645. https://doi.org/10.3389/fphys.2022.833645CrossRefPubMedPubMedCentral

Mathew PG, Klein BC (2019) Getting to the heart of the matter: migraine, triptans, DHE, ditans, CGRP antibodies, first/second-generation gepants, and cardiovascular risk. Headache 59:1421–1426. https://doi.org/10.1111/head.136012CrossRefPubMed

Dodick DW, Tepper SJ, Ailani J, Pannacciulli N, Navetta MS, Loop B, Zhang F, Khodavirdi AC, Mann A, Abdrabboh A, Kalim J (2021) Risk of hypertension in erenumab-treated patients with migraine: analyses of clinical trial and postmarketing data. Headache 61:1411–1420. https://doi.org/10.1111/head.14208CrossRefPubMedPubMedCentral

10.

Booth CM, Tannock IF (2014) Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer 110:551–555. https://doi.org/10.1038/bjc.2013.725CrossRefPubMedPubMedCentral

11.

Bigal ME, Kurth T, Hu H, Santanello N, Lipton RB (2009) Migraine and cardiovascular disease: possible mechanisms of interaction. Neurology 72:1864–1871. https://doi.org/10.1212/WNL.0b013e3181a71220CrossRefPubMedPubMedCentral

12.

Stergiou GS, Mukkamala R, Avolio A, Kyriakoulis KG, Mieke S, Murray A, Parati G, Schutte AE, Sharman JE, Asmar R, RJ MM, Asayama K, De La Sierra A, Head G, Kario K, Kollias A, Myers M, Niiranen T, Ohkubo T et al (2022) Cuffless blood pressure measuring devices: review and statement by the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. J Hypertens 40:1449–1460. https://doi.org/10.1097/HJH.0000000000003224CrossRefPubMed

13.

de Vries LS, van der Arend BWH, Maassen VanDenBrink A, Terwindt GM (2022) Blood pressure in patients with migraine treated with monoclonal anti-CGRP (receptor) antibodies: a prospective follow-up study. Neurology 99:e1897–e1904. https://doi.org/10.1212/WNL.0000000000201008CrossRef

14.

Elgendy IY, Nadeau SE, Bairey Merz CN, Pepine CJ (2019) American College of Cardiology Cardiovascular Disease in Women Committee Migraine headache: an under-appreciated risk factor for cardiovascular disease in women. J Am Heart Assoc 8:e014546. https://doi.org/10.1161/JAHA.119.014546

15.

Kurth T, Rist PM, Ridker PM, Kotler G, Bubes V, Buring JE (2020) Association of migraine with aura and other risk factors with incident cardiovascular disease in women. JAMA 323:2281–2289. https://doi.org/10.1001/jama.2020.7172CrossRefPubMedPubMedCentral

16.

Wang K, Mao Y, Lu M, Ding Y, Li Z, Li Y, Liu X, Sun Y, Hong J, Xu D, Wu T (2022) Association between migraine and cardiovascular disease: a cross-sectional study. Front Cardiovasc Med 9:1044465. https://doi.org/10.3389/fcvm.2022.1044465CrossRefPubMedPubMedCentral

17.

Sohn I, Sheykhzade M, Edvinsson L, Sams A (2020) The effects of CGRP in vascular tissue - classical vasodilation, shadowed effects and systemic dilemmas. Eur J Pharmacol 881:173205. https://doi.org/10.1016/j.ejphar.2020.173205CrossRefPubMed

18.

Brain SD, Tippins JR, Morris HR, MacIntyre I, Williams TJ (1986) Potent vasodilator activity of calcitonin gene-related peptide in human skin. J Invest Dermatol 87:533–536. https://doi.org/10.1111/1523-1747.ep12455620CrossRefPubMed

19.

Uddman R, Edvinsson L, Jansen I, Stiernholm P, Jensen K, Olesen J, Sundler F (1986) Peptide-containing nerve fibres in human extracranial tissue: a morphological basis for neuropeptide involvement in extracranial pain? Pain 27:391–399. https://doi.org/10.1016/0304-3959(86)90162-4CrossRefPubMed

20.

Ye F, Deng PY, Li D, Luo D, Li NS, Deng S, Deng HW, Li YJ (2007) Involvement of endothelial cell-derived CGRP in heat stress-induced protection of endothelial function. Vascul Pharmacol 46:238–246. https://doi.org/10.1016/j.vph.2006.10.008CrossRefPubMed

21.

Krämer HH, Schmidt K, Leis S, Schmelz M, Sommer C, Birklein F (2006) Angiotensin converting enzyme has an inhibitory role in CGRP metabolism in human skin. Peptides 27:917–920. https://doi.org/10.1016/j.peptides.2005.08.007CrossRefPubMed

22.

Edvinsson L, Chan KY, Eftekhari S, Nilsson E, de Vries R, Säveland H, Dirven CM, Danser AH, MaassenVanDenBrink A (2010) Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries. Cephalalgia 30:1233–1240. https://doi.org/10.1177/0333102410362122CrossRefPubMed

23.

Jansen-Olesen I, Jørgensen L, Engel U, Edvinsson L (2003) In-depth characterization of CGRP receptors in human intracranial arteries. Eur J Pharmacol 481:207–216. https://doi.org/10.1016/j.ejphar.2003.09.021CrossRefPubMed

24.

Chan KY, Edvinsson L, Eftekhari S, Kimblad PO, Kane SA, Lynch J, Hargreaves RJ, de Vries R, Garrelds IM, van den Bogaerdt AJ, Danser AH, Maassenvandenbrink A (2010) Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries. J Pharmacol Exp Ther 334:746–752. https://doi.org/10.1124/jpet.110.165993CrossRefPubMed

25.

Eftekhari S, Warfvinge K, Blixt FW, Edvinsson L (2013) Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain 14:1289–1303. https://doi.org/10.1016/j.jpain.2013.03.010CrossRefPubMed

26.

Wellman GC, Quayle JM, Standen NB (1998) ATP-sensitive K+ channel activation by calcitonin gene-related peptide and protein kinase A in pig coronary arterial smooth muscle. J Physiol 507:117–129. https://doi.org/10.1111/j.1469-7793.1998.117bu.xCrossRefPubMedPubMedCentral

27.

Yoshimoto R, Mitsui-Saito M, Ozaki H, Karaki H (1998) Effects of adrenomedullin and calcitonin gene-related peptide on contractions of the rat aorta and porcine coronary artery. Br J Pharmacol 123:1645–1654. https://doi.org/10.1038/sj.bjp.0701805CrossRefPubMedPubMedCentral

28.

Brain SD, Grant AD (2004) Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 84:903–934. https://doi.org/10.1152/physrev.00037.2003CrossRefPubMed

29.

Juhl L, Edvinsson L, Olesen J, Jansen-Olesen I (2007) Effect of two novel CGRP-binding compounds in a closed cranial window rat model. Eur J Pharmacol 567:117–124. https://doi.org/10.1016/j.ejphar.2007.04.004CrossRefPubMed

30.

Schain AJ, Melo-Carrillo A, Stratton J, Strassman AM, Burstein R (2019) CSD-induced arterial dilatation and plasma protein extravasation are unaffected by fremanezumab: implications for CGRP's role in migraine with aura. J Neurosci 39:6001–6011. https://doi.org/10.1523/JNEUROSCI.0232-19.2019CrossRefPubMedPubMedCentral

31.

Edvinsson L, Nilsson E, Jansen-Olesen I (2007) Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. Br J Pharmacol 150:633–640. https://doi.org/10.1038/sj.bjp.0707134CrossRefPubMedPubMedCentral

32.

Edvinsson L, Ekman R, Thulin T (1989) Circulating perivascular dilatory neuropeptides in hypertension. J Hypertens Suppl 7:S194–S195. https://doi.org/10.1097/00004872-198900076-00093CrossRefPubMed

33.

Schifter S, Krusell LR, Sehested J (1991) Normal serum levels of calcitonin gene-related peptide (CGRP) in mild to moderate essential hypertension. Am J Hypertens 4:565–569. https://doi.org/10.1093/ajh/4.7.565CrossRefPubMed

34.

Masuda A, Shimamoto K, Mori Y, Nakagawa M, Ura N, Iimura O (1992) Plasma calcitonin gene-related peptide levels in patients with various hypertensive diseases. J Hypertens 10:1499–1504. https://doi.org/10.1097/00004872-199210120-00010CrossRefPubMed

35.

Portaluppi F, Trasforini G, Margutti A, Vergnani L, Ambrosio MR, Rossi R, Bagni B, Pansini R, Degli Uberti EC (1992) Circadian rhythm of calcitonin gene-related peptide in uncomplicated essential hypertension. J Hypertens 10:1227–1234. https://doi.org/10.1097/00004872-199210000-00017CrossRefPubMed

36.

Edvinsson L, Erlinge D, Ekman R (1992) Thulin T (1992) Sensory nerve terminal activity in severe hypertension as reflected by circulating calcitonin gene-related peptide (CGRP) and substance P. Blood Press 1:223–229. https://doi.org/10.3109/08037059209077667CrossRefPubMed

37.

Lind H, Brudin L, Lindholm L, Edvinsson L (1996) Different levels of sensory neuropeptides (calcitonin gene-related peptide and substance P) during and after exercise in man. Clin Physiol 16:73–82. https://doi.org/10.1111/j.1475-097x.1996.tb00557.xCrossRefPubMed

38.

Li J, Wang DH (2005) Development of angiotensin II-induced hypertension: role of CGRP and its receptor. J Hypertens 23:11311–11318. https://doi.org/10.1097/00004872-200501000-00020CrossRef

39.

Strecker T, Dux M, Messlinger K (2002) Increase in meningeal blood flow by nitric oxide--interaction with calcitonin gene-related peptide receptor and prostaglandin synthesis inhibition. Cephalalgia 22:233–241. https://doi.org/10.1046/j.1468-2982.2002.00356.xCrossRefPubMed

40.

Etefagh HH, Shahmiri SS, Melali H, Sayadi M, Ansari H, Shahzamani A, Deyhimi MS (2022) Bariatric surgery in migraine patients: CGRP level and weight loss. Obes Surg 32(11):3635–3640. https://doi.org/10.1007/s11695-022-06218-2CrossRefPubMed

Title: Evaluation of the risk of hypertension in patients treated with anti-CGRP monoclonal antibodies in a real-life study
Authors: Simona Guerzoni
Flavia Lo Castro
Daria Brovia
Carlo Baraldi
Luca Pani
Publication date: 06-11-2023
Publisher: Springer International Publishing
Keywords: Migraine
Erenumab
Fremanezumab
Hypertension
Galcanezumab
Hypertension
Published in: Neurological Sciences / Issue 4/2024
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-023-07167-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Evaluation of the risk of hypertension in patients treated with anti-CGRP monoclonal antibodies in a real-life study

Abstract

Objective

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2024

Incidence of amyotrophic lateral sclerosis-associated genetic variants: a clinic-based study

Safety and neutralization antibody levels of inactivated SARS-CoV-2 vaccine in adult patients with Myasthenia Gravis: a prospective observational cohort study

Dural arteriovenous fistula presenting with recurrent focal status epilepticus and lateralised periodic epileptiform discharges

When the brain moves away: a case of sphenoidal sinus encephalocele

Hyperhidrosis as the initial symptom in FUS mutation-associated amyotrophic lateral sclerosis: a case report and comprehensive literature review

Effects of immediate thrombolytic treatment in imaging area on functional outcome in patients with acute ischemic stroke